Navigation Links
UK’s Junior Doctors Losing Hop

A pall of gloom and associated pessimism hangs thickly over Britain’s junior doctors,// reports show.

It has just been a month since UK’s young doctors took the street in protest of the lack of suitable jobs. This was in spite of most of them having dished out thousands of pounds to train for government programs that would make them eligible for NHS employment. The dearth of jobs, they argue is due to the Department of Health ‘s scheme, the Medical Training Application Service (MTAS) having gone horribly wrong.

Yesterday the chairman of the British Medical Association (BMA) called for a "cast-iron" guarantee that no junior doctor will lose out as a result of reforms to the training system. According to James Johnson, the careers of thousands of aspiring young doctors could be wrecked by the changes.

Complaints registered over the MTAS include lack of sufficient job choices, computers crashing, non-medically qualified people being involved in short-listed candidates and scant information on qualifications being made available to interviewers.

According to the BMA, latest figures have showed that 34,250 junior doctors throughout the UK are applying for just 18,500 specialist-training posts.

Says Johnson: "It's disgraceful that thousands of our best doctors could have their NHS careers wrecked through no reason other than government mistakes and poor workforce planning. "For the sake of patients who deserve the best possible care, and to ensure an NHS staffed by fully trained doctors, we need solutions that ensure that no-one is forced out of training. "People who have worked for years to follow their ambitions of becoming NHS consultants or GPs cannot be thrown on the scrap heap."

In addition, latest BMA research suggests deep-rooted dissatisfaction with how the NHS is evolving. Asked how the NHS would look in 2017, 94% of young doctors said they thought the role of the private sector woul
'"/>




Page: 1 2

Related medicine news :

1. Junior Doctors Working Long Hours May Perform Poorly
2. Junior Doctors Put An End To Strike
3. Andhra Junior Doctors Call Off Strike Partially; To Attend Emergency cases
4. Parents of Junior Athletes do More Harm than Good
5. Junior Medicos Call Off Hunger Strike
6. MP Junior Doctors Continue Strike
7. Several Junior Doctors Could Be Rendered Jobless
8. Junior Doctors Back To Work
9. Junior Doctors In Madhya Pradesh Strike Work
10. Junior Doctors Protest Against Reservation Bill
11. Envisaged Specialty Training Programme For Junior Doctors Encounters a Speed Breaker
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Junior Doctors Losing Hop

(Date:9/5/2008)...at triggers them, experts say , , FRIDA...he 36 million Americans who suffer from seasonal a...at is free from pollen and other allergens this fa...happen in the spring, they can be bothersome in ot...ging cities to live in are Greensboro, N.C., Green...
(Date:9/5/2008)... Tonight is a momentous,occasion as the three majo...utives, celebrities and prominent leaders in cance...nd Up to Cancer. This collaboration,featuring a o...n the three,networks -- ABC, CBS and NBC -- offers...on about cancer and the need to take action., For...
(Date:9/5/2008)...ht or obese at age 45 , , FRIDAY, Sept. ...adults will develop osteoarthritis of the knee by ...in middle age, a new study says. , A person,s ...his or her body-mass index (BMI) rose, according t...study. People who were of normal weight at age 18 ...
(Date:9/5/2008)...,s Annual Destination to Feature VelaShape. , ...eptember 5, 2008 -- http://www.americanlaser.com ..., the largest provider of laser hair removal and o...nnounces sponsorship of the STYLE360 show during N...serves as the alternative Fashion Week destination...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2
...disorders ahs been found out .This may lead to a m.... Researchers were able to develop a diagnostic te...most patients with myeloproliferative blood disord...y an overproduction of blood cells and can cause h...
...n found out that there is no association between a...ood -- and breast cancer. More than 43,000 women w...patients. The participants had their average daily...ence of an increased risk of breast cancer in the ...
...ced in the pancreas, but in the brain as well. Whe...ult can be brain cell death and subsequent develop...Alzheimer’s. The research was conducted in rats, a...s growth factors IGF I and IGF II were produced in...
... Association for Dental Research held in Baltimore...ts of a study// that says eating sugar-free yogurt...l bad odor or so called bad breath is caused by ha...ike hydrogen sulfide. The study revealed that volu...
Other Medicine News:
(Date:9/3/2008)...ional Vascular Disease Awareness Month, CHARLOTTE...rmaceuticals,LLC, a clinical-stage drug-developmen...ent of unmet medical needs, announced today that i...nical trial of its lead drug,candidate trans sodiu...5881,on the clinicaltrials.gov Website, is investi...
(Date:9/3/2008)... Multaq(R) (dronedarone) decreased the risk of,str...atrial flutter already adequately tre..., Sept. 3 /- The results of...tudy were presented today at,the clinical trial up...,congress 2008, in Munich, Germany. Previous resul...
(Date:9/3/2008)...firms Strong Evidence Pycnogenol(R) Lowers Joint, ...nts Following Cessation ...ire/ -- According to the Center for,Disease Contro...rthritis,is on the rise. A new study published in...als Pycnogenol(R), bark extract from the French ma...
(Date:9/2/2008)...wswire-FirstCall/ -- Forest Laboratories, Inc.,(NY...nnounced results from,two global Phase III studies...d anticholinergic for the treatment of patients wi...n both the ACCLAIM/COPD I&II,(AClidinium CLinical ...,Severe COPD Patients) studies, once-daily aclidin...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 1Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 2Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 3Stryker to Present at Investor Conferences 8474 1Stryker to Present at Investor Conferences 8474 2Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 1Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 2Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 3Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 4Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 5
...lot Study Demonstrates 50% Survival in Valortim-Tr..., March 29, 2007 - Medarex,Inc. (Nasdaq: MEDX), a...ene, Inc., a privately held biotechnology company ...measures, today announced,that Valortim, a fully h...eveloped for the prevention and treatment of anthr...
...LLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstC... , Solvay,Pharmaceuticals, Inc. and Lundbeck A/S p...n international medical congress this,week. Safety...reatment for adult patients diagnosed with schizop... lipid profile, similar to,placebo. In addition, i...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa
... fit in tight spaces easily? Introducing the Guida... innovation in mechanical tissue stabilization.,T...low-profile feet, innovative FlexLink technology, ...ability, and access to target vessels.,Include th...
The AB-180 iVAD*, implantable ventricular assist device, is a surgically implantable device used by cardiac surgeons. The inflow and outflow conduits are pre-attached to the VAD and anatomically posi
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus
Medicine Products: